The acceptance of cannabis's medical use by eight states
[between 1996 and 2002] and the experiences of patients,
doctors, and state officials in these states establish
marijuana's accepted medical use in the United States.
Cannabis's accepted medical use in the United States
is increasingly recognized by health care professionals
and the medical community, including the Institute of
Medicine. Several medical organizations support legal
access to cannabis for medicinal purposes. A new medical
journal released in 2001 focuses on the medicinal use
of cannabis and cannabinoids. National clinical conferences
on the medicinal use of cannabis have been held in the
United States in 2000 and 2002 and are scheduled to
continue on a bi-annual basis.. Most importantly, data
on the number of physicians currently recommending therapeutic
marijuana use to their patients demonstrate its acceptance
by the medical community in the United States. More...
Patients' experience and their confirmation
by early studies
Following state laws that allow for the medical use
of cannabis, an increasing number of patients have collected
experience with cannabis. Many reported benefits from
its use. Some of this experience has been confirmed
in reports and clinical investigations or stimulated
clinical research that confirmed these patients' experience
on other patients suffering from the same disease. More...
Reviews of earlier clinical studies
Several scientific publications have reviewed evidence
from research on the medicinal uses of cannabis indicating
that cannabis in fact may offer benefits in the treatment
of certain illnesses. More...
The scientific understanding of the endogenous cannabinoid
system consisting of specific cannabinoid receptors
and their endogenous ligands (endocannabinoids) has
considerably increased since 1995. It largely supports
and helps explain many of the therapeutic benefits of
cannabis and cannabinoids in humans. More...
Results from clinical research demonstrate that both
dronabinol and whole plant cannabis can offer a safe
and effective treatment for the following illnesses:
muscle spasms in multiple sclerosis, Tourette syndrome,
chronic pain, nausea and vomiting in HIV/AIDS and cancer
chemotherapy, loss of appetite from cancer, hyperactivity
of the bladder in patients with multiple sclerosis and
spinal cord injury, and dyskinesia caused by levodopa
in Parkinson's disease. More...
Route of administration.
Progress has been made in recent years in reducing
the disadvantages of certain routes of cannabis administration,
notably the slow onset of action with oral use and harm
associated with the inhalation of combustion products
when smoking cannabis. More...
The pharmaceutical industry is showing not only increasing
interest in synthetic modulators of the endogenous cannabinoid
system, but also industry members are funding several
clinical studies with cannabis whole plant extracts
in Europe and Canada with the intention to develop approved
cannabis based medicines. This indicates that therapeutic
exploitation of natural cannabis will be economically
sound. However the present Schedule I classification
of cannabis and THC is an impediment to the pharmaceutical
development of cannabinoid drugs becaused of the costly
restrictions it places on research. More...